17:51 , Jan 11, 2019 |  BC Week In Review  |  Clinical News

BlackThorn deprioritizing MDD compound after Phase IIa miss

BlackThorn Therapeutics Inc. (San Francisco, Calif.) said it will deprioritize development of BTRX-246040 (formerly LY-2940094) to treat major depressive disorder (MDD) after the compound missed the primary and secondary endpoints in a Phase IIa trial....
06:11 , Aug 10, 2018 |  BC Week In Review  |  Company News

BlackThorn licenses Yale's neuroimaging tech

Neurobehavioral disorder company BlackThorn Therapeutics Inc. (San Francisco, Calif.) exclusively licensed neuroimaging technology from Yale University School of Medicine designed to link gene expression patterns with behavioral circuits in the brain. Yale has dubbed the...
23:38 , Aug 6, 2018 |  BC Extra  |  Company News

BlackThorn licenses Yale's neuroimaging drug discovery tech

Neurobehavioral disorder company BlackThorn Therapeutics Inc. (San Francisco, Calif.) exclusively licensed neuroimaging technology from Yale University School of Medicine designed to link gene expression patterns with behavioral circuits in the brain. Yale has dubbed the...
19:19 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

BlackThorn brings KOR antagonist into clinic

BlackThorn Therapeutics Inc. (San Francisco, Calif.) began a Phase I trial evaluating up to seven single and multiple ascending doses of BTRX-335140 to assess dose exposure and safety in about 90 healthy volunteers. The company...
20:48 , Jul 28, 2017 |  BioCentury  |  Product Development

Circuit logic

BlackThorn Therapeutics Inc. has begun the first of a series of studies that will test whether it can solve a tough problem in neurological drug development: the tendency of heterogeneity among patients with the same...